Hello Customer,

c-Met (MET or mesenchymal-epithelial transition factor) is a prototype member of a subfamily of heterodimeric receptor tyrosine kinases (RTKs) and is the receptor for hepatocyte growth factor (HGF). Activation of the MET receptor leads to the activation of downstream signals, including the mitogen-activated protein kinase (ERK/ MAPK) and phosphatidylinositol 3-kinase (PI3K/AKT) pathways, STAT3, and RAS. Dysregulated HGF/c-Met signaling is a driving factor for several malignancies and promotes tumor growth, invasion, dissemination and angiogenesis. c-Met kinase has emerged as a promising target for cancer drug development. BioVision is proud to offer several structurally diverse small molecule c-Met kinase inhibitors for research.

Key Features:

• Highly Potent, Selective & Cell -permeable Inhibitors

• Many Inhibitor Options to Choose From

• Cost-Effective